GLP-1 receptor agonists, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have revolutionised the treatment of type 2 diabetes and obesity
IGF-1LR3 and Cognition Research shows that IGF-1 protect the loss of neurons by stimulating cellular process that promotes cell survival
This comprehensive strategy can lead to symptom alleviation and substantial improvements in gastrointestinal well-being, potentially marking a significant advance in the treatment of these challenging conditions
* Doses given are for adult male
1 - a valuable medicinal plant
Without alternative diabetes management strategies in place, this can result in hyperglycaemia, with symptoms including increased thirst, frequent urination, fatigue, and blurred vision